MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Celldex Therapeutics Inc

Fechado

SetorSaúde

27.15 3.67

Visão Geral

Variação de preço das ações

24h

Atual

Mín

25.88

Máximo

27.77

Indicadores-chave

By Trading Economics

Rendimento

-2.8M

-57M

Vendas

35K

730K

Margem de lucro

-7,753.425

Funcionários

186

EBITDA

-1.1M

-63M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+99.77% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

304M

1.8B

Abertura anterior

23.48

Fecho anterior

27.15

Sentimento de Notícias

By Acuity

21%

79%

48 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de out. de 2025, 16:58 UTC

Ganhos

BMW Trims 2025 View, Citing Weaker Performance in China

7 de out. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 de out. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 de out. de 2025, 23:19 UTC

Conversa de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 de out. de 2025, 22:40 UTC

Conversa de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 20:44 UTC

Ações em Alta

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 de out. de 2025, 19:42 UTC

Conversa de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 de out. de 2025, 19:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 de out. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 de out. de 2025, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 de out. de 2025, 15:33 UTC

Conversa de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 de out. de 2025, 15:25 UTC

Conversa de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 de out. de 2025, 15:15 UTC

Conversa de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 de out. de 2025, 14:52 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

99.77% parte superior

Previsão para 12 meses

Média 52.38 USD  99.77%

Máximo 67 USD

Mínimo 38 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

10

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

48 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat